Tradonal

Quick links to important sections

Tradonal

Treatment option: Pain, Chronic Pain

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tradonal

Property Description
Active Ingredient Tramadol Hydrochloride
Pharmacological Class Opioid Analgesic; Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Common Use Relief of moderate to moderately severe pain
Origin Synthetic opioid analogue
Key Forms Tablets, Capsules, Oral Solution, Injection

What Type of Analgesic is Tradonal (Tramadol Hydrochloride)?

Tradonal is defined by its core active substance, Tramadol Hydrochloride, and is classified as a synthetic opioid analgesic that acts centrally to modulate pain. The substance is structurally related to codeine, but its clinical distinction is its multimodal mechanism of action. It uniquely combines the essential traits of an opioid agonist with the neurochemical properties of a Serotonin–Norepinephrine Reuptake Inhibitor (SNRI).

This combined activity establishes it as a powerful, prescription-only medication. Due to its potential for misuse and dependence, Tramadol is placed in Schedule IV, highlighting its regulated identity.


How Does Tradonal's Structure Define Its General Purpose?

The drug’s unique structure enables it to suppress discomfort by engaging two complementary pathways. The active substance and its primary metabolite, O-desmethyltramadol (M1 metabolite), engage the mu-opioid receptors to directly dampen the intensity of pain signals. Simultaneously, the drug enhances the availability of the neurotransmitters serotonin and norepinephrine, which are key components of the body's intrinsic descending pain control system.

This clinically recognized multimodal action provides a comprehensive strategy for managing both acute pain and chronic pain, confirming its general purpose in situations where single-pathway analgesics may be insufficient.


Available Forms of Tradonal (Tablets, Solutions, and Injections)

Tradonal is supplied in diverse dosage forms tailored to different therapeutic requirements, including standard tablets and capsules for oral ingestion, a liquid oral solution (drops), and a sterile preparation for injection. The formulations are distinguished primarily by their duration of action, offering both immediate-release versions, intended for quick effect, and extended-release versions, which are specially designed to release the drug gradually over a prolonged period. This variation ensures the medication can be strategically employed for either rapid intervention or sustained, steady maintenance of pain control.

What side effects are possible with Tradonal?

Possible Side Effects and Safety Information

Tradonal (Tramadol Hydrochloride) is an opioid analgesic and carries a Boxed Warning—the strongest warning required by regulatory authorities—due to the risk of serious and life-threatening adverse effects.

Adverse Reaction Scope

Classification Examples of Reactions
Most Common (Reported ge 10%) Nausea, constipation, dizziness/vertigo, somnolence (sleepiness), vomiting, dry mouth, headache.
System-Organ Classes Nervous System (e.g., seizures), Gastrointestinal (e.g., paralytic ileus), Respiratory (e.g., depression), Psychiatric (e.g., addiction/abuse), and Vascular (e.g., severe hypotension).

Serious Adverse Reactions (Label-Documented)

  • Life-Threatening Respiratory Depression: Serious breathing difficulty, which can be fatal. Risk is highest when treatment begins or following a dose increase.
  • Addiction, Abuse, and Misuse: Risk exists even at recommended doses. Requires monitoring and a Risk Evaluation and Mitigation Strategy (REMS) is mandated by the FDA.
  • Serotonin Syndrome: A potentially life-threatening condition linked to the medicine's activity and increased by concomitant use of certain other medicines (e.g., some antidepressants).
  • Seizures: Can occur even at recommended doses; the risk increases with higher doses or in patients with predisposing factors.
  • Neonatal Opioid Withdrawal Syndrome (NOWS): Prolonged use during pregnancy can result in this life-threatening withdrawal syndrome in the newborn.
  • Adrenal Insufficiency and Severe Hypotension (low blood pressure).

Safety-Related Restrictions and Limitations

Tradonal is contraindicated in several specific circumstances, including in children under 12 years of age, and in those under 18 following tonsillectomy/adenoidectomy, due to the risk of ultra-rapid metabolism. Use is also restricted in patients with severe respiratory depression, acute or severe asthma, or who are taking Monoamine Oxidase Inhibitors (MAOIs). Using this medicine with other Central Nervous System (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Patients should be cautious when driving or operating machinery.

Overdose and Emergency Response

Overdose and when to seek help

Tradonal overdose is classified by regulatory authorities as a severe, potentially life-threatening event requiring immediate medical intervention. Documented overdose presentations often involve significant Central Nervous System (CNS) and respiratory depression, which can progress to profound somnolence, coma, and life-threatening respiratory arrest. Opioid-specific signs such as pinpoint pupils (miosis) are frequently noted in the official documentation.

In addition to the primary opioid toxicity, the drug's non-opioid activity introduces specific risks. The official documentation identifies the potential for generalized seizures or convulsions, as well as the occurrence of the severe condition known as Serotonin Syndrome. Severe outcomes listed in regulatory documents include cardiovascular collapse and cardiac arrest.

Immediate emergency medical attention is required for any suspected overdose. This mandate is critical due to the rapid onset of CNS and respiratory compromise. In a clinical setting, management is symptomatic and supportive. While Naloxone may be administered to reverse the respiratory depression caused by the opioid component, official labeling notes that it may have limited or no effect on other serious toxicities, such as overdose-induced seizures. Treatment protocols also include continuous monitoring of cardiac and respiratory status and the use of supportive measures to manage specific symptoms.

Therapeutic Uses of Tradonal

Quick Facts About Tradonal

  • Approved Use: Management of moderate to moderately severe pain.
  • Context: For pain that requires an opioid analgesic, especially when alternative options have been inadequate or not tolerated.
  • Formulations: Available in both immediate-release and extended-release formats.

Tradonal is a prescription medication utilized for the management of pain that is categorized as moderate to moderately severe. It is primarily indicated for use in adults when the severity of pain requires an opioid treatment and when other analgesic options have not provided sufficient relief or cannot be used. The treatment is intended to modulate the patient's perception of pain by acting on the central nervous system.

The extended-release formulations are specifically indicated for chronic pain that necessitates daily, around-the-clock analgesic treatment for an extended period. The goal of treatment is to support the patient's comfort and improve their ability to manage the condition. Before beginning treatment, all individuals should have a thorough discussion with their healthcare provider regarding the potential benefits and risks associated with this type of pain management. This medication is approved for specific prescribed indications.

Eligibility and Restrictions for Use

Who Can and Cannot Use Tradonal?

The official regulatory profile for Tradonal (Tramadol Hydrochloride) establishes strict eligibility criteria based on patient population and underlying health status.

Eligibility Domain Status Key Restriction
Absolute Contraindications Prohibited Hypersensitivity, severe respiratory depression, acute intoxication (alcohol, opioids, CNS depressants), or concurrent use of Monoamine Oxidase Inhibitors (MAOIs).
Pediatric Eligibility Contraindicated Use is contraindicated in all children younger than 12 years of age. Use is also prohibited in adolescents younger than 18 following tonsillectomy or adenoidectomy.
Organ Function Restricted Severe hepatic impairment and severe renal impairment (creatinine clearance < 30 mL/min) necessitate restricted use and are generally not recommended due to delayed elimination.
Reproductive Status Not Recommended Not recommended during pregnancy due to the risk of Neonatal Opioid Withdrawal Syndrome. Not recommended during breastfeeding.

The eligibility profile is primarily defined by mandatory Contraindications that absolutely prohibit use in specific acute conditions and for patients taking certain drug classes. Further Restrictions apply to patient populations whose physiological status, such as compromised liver or kidney function, significantly alters drug clearance. The drug is otherwise allowed for use in adults 18 years of age and older who require opioid analgesia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The use of Tradonal with many other medicines may lead to serious or life-threatening adverse reactions. The following categories and specific agents are noted in regulatory documents due to clinically significant interactions.

Interacting Agents/Classes Risk/Effect Classification/Restriction
CNS Depressants (including benzodiazepines, hypnotics, sedatives, other opioids, alcohol) Profound sedation, respiratory depression, coma, and death. Use with caution, limit dose/duration. Avoid alcohol.
Serotonergic Drugs (e.g., SSRIs, SNRIs, Triptans, Tricyclic Antidepressants, St. John's Wort) Increased risk of Serotonin Syndrome, a potentially life-threatening condition. Use with caution, monitor for symptoms.
Monoamine Oxidase Inhibitors (MAOIs) High risk of Serotonin Syndrome and other serious events. Contraindicated. Must wait 14 days after stopping an MAOI.
CYP2D6 & CYP3A4 Inhibitors/Inducers (e.g., Quinidine, Fluoxetine, Carbamazepine) Altered drug metabolism, potentially reducing analgesic effect or increasing adverse effects like seizures and respiratory depression. Carbamazepine notably reduces analgesic effect. Requires careful consideration and monitoring.
Drugs that lower seizure threshold (e.g., Neuroleptics, other opioids, SSRIs/SNRIs) Increased risk of seizures. Use with caution.
Mixed Agonist/Antagonist Opioids (e.g., Buprenorphine, Nalbuphine) Reduced analgesic effect of Tradonal or precipitated withdrawal symptoms. Avoid concomitant use.

Co-administration with Digoxin or Warfarin has been associated with rare reports of digoxin toxicity and altered effects on prothrombin time, respectively.

Mechanism of Action

Tradonal exerts its effect through a multimodal mechanism primarily focused on modulating pain signaling within the central nervous system (CNS). This approach targets two distinct, synergistic physiological pathways to attenuate nociceptive signal transmission.

Direct Activation of mu-Opioid Receptors

This domain covers the direct engagement of inhibitory mu-opioid receptors (mu-OR) by the active metabolite, O-desmethyltramadol (M1). By binding to these receptors in the brain and spinal cord, the mechanism initiates a cascade that reduces the release of pain-transmitting neurotransmitters, leading to the physiological consequence of attenuation of nociceptive signal transmission.

Enhancement of the Descending Inhibitory Pathways

This domain addresses the drug’s function as an inhibitor of the Norepinephrine and Serotonin Transporters (NET/SERT). This action increases the availability of these monoamines at the synapse, resulting in the enhancement of the descending inhibitory pain pathways that modulate nociceptive signal propagation in the spinal cord, working synergistically with the receptor-mediated actions.

Mechanism Dependency on Metabolism

A key constraint on the drug's action is its dependence on metabolic conversion via the CYP2D6 enzyme to form the potent M1 metabolite. This conversion is necessary for robust mu-OR agonism; therefore, reduced enzyme activity limits the functional contribution of the opioid-mediated mechanism.

Dosage and Administration Information

How Tradonal is Used

The use of Tradonal (Tramadol Hydrochloride) is strictly governed by the intended duration and release type of the formulation. The medicine is primarily administered via the oral route (tablets, capsules, or solution), although a sterile preparation exists for parenteral use.

Standard Administration and Scheduling

The official dosing protocol distinguishes between immediate-release (IR) and extended-release (ER) forms. IR formulations, typically dosed at 50 mg to 100 mg per dose, are administered as needed every four to six hours, with the total daily dose not exceeding 400 mg. In contrast, ER forms are dosed once daily (qDay) for continuous, round-the-clock use, with a maximum of 300 mg per day. When initiating ER therapy, the starting dose is often 100 mg once daily, with adjustments occurring no more frequently than every five days.

Special Administration Requirements

The integrity of the dosage form is critical for proper use. Extended-release tablets or capsules must be swallowed whole and cannot be crushed, chewed, split, or dissolved, as this bypasses the controlled-release mechanism. The medication may be taken with or without food, but consistency is recommended. Official guidelines also establish a governing principle that treatment should always employ the lowest effective dosage for the shortest duration consistent with treatment goals.

Population Adjustments

Dose adjustment is required for specific patient groups. For older adults (over 75 years), the daily maximum dose for IR formulations is restricted to 300 mg. Patients with severe renal impairment (creatinine clearance less than 30 mL/min) must extend the dosing interval to every 12 hours, and extended-release forms are generally not recommended in this group. Use is also officially restricted in children younger than 12 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tradonal


Evidence for Acute Pain Management

Research on the use of Tradonal for short-term pain primarily comes from short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were used in research exploring how symptoms change over time and typically monitored patient-reported outcomes describing perceived discomfort over periods ranging from a few hours up to one or two days. Findings describe patterns related to changes in pain scores compared to control groups. However, the follow-up durations were limited, focusing solely on the immediate post-event period.

Evidence for Chronic Non-Cancer Pain

The research for long-term conditions like osteoarthritis involves intermediate-term RCTs and Systematic Reviews. These studies research examined treatment for conditions marked by functional limitations, measuring physical functioning and quality of life scores over periods up to 16 weeks. Scientific reviews indicate that the average size of the measured change was sometimes considered to be below the minimal clinically important difference. For this reason, and due to limited follow-up, the certainty remains low for the long-term maintenance of observed functional patterns.

Evidence in Special Patient Populations and Key Limitations

Research was studied for use in older adults and those with comorbid conditions such as painful diabetic neuropathy. For other groups, including pediatric patients, data remain insufficient, and data for use in these groups remain highly limited. The overall research base is limited by short follow-up and modest sample sizes in some trials, meaning long-term effects are not fully established. Furthermore, comparative evidence is lacking for many direct head-to-head scenarios against other available analgesic options.

Key Studies & References

  1. Tramadol for chronic non-cancer pain: a systematic review with meta-analysis (MCID and Low Certainty Evidence)
  2. WHO Analgesic Ladder and Opioid Classification in Palliative Care

Frequently Asked Questions (FAQ)

Common questions about Tradonal (FAQ)


Q: Can I take Tradonal if I'm already taking supplements?

A: Regulatory guidance warns that Tradonal interacts with medicines that affect the serotonergic neurotransmitter system. This category can include certain herbal supplements, such as St. John's Wort. Informing a healthcare professional about all supplements is an important step to help avoid potential serious interactions.


Q: Are there any specific foods I should avoid while on Tradonal?

A: According to the official product information, Tradonal may be taken either with or without food. There are no specific foods listed in regulatory documents that must be avoided. For extended-release forms, consistency in taking the medicine (with or without food) is generally noted, and consumption of alcohol should be avoided.


Q: Is it safe to drink alcohol in moderation while taking Tradonal?

A: Regulatory documents indicate that the use of alcohol is strongly discouraged while taking Tradonal. Combining this drug with alcohol carries a significant safety risk related to central nervous system depression. This risk can include profound sedation, respiratory depression, and coma.


Q: What happens if I miss a dose of Tradonal?

A: Regulatory guidance suggests that if a dose is missed, it should generally be skipped, and the patient should continue with the regular schedule. Official patient instructions advise against taking a double dose to compensate for the one that was missed.


Q: Can Tradonal affect my sleep?

A: Yes, official regulatory labels list several side effects related to the central nervous system that can affect sleep. These commonly include somnolence (sleepiness) and dizziness. The drug’s effects on the nervous system may lead to general sleep disturbances or disorders.


Q: Does Tradonal have a risk of dependence or withdrawal symptoms?

A: Yes. As an opioid analgesic, Tradonal carries risks of physical dependence, addiction, abuse, and misuse, even when taken as directed. Abrupt discontinuation in physically dependent individuals can lead to withdrawal symptoms. Dose reduction is typically managed by a healthcare professional to minimize risk.


Q: How long can I safely take Tradonal?

A: Regulatory guidance stresses that treatment should always employ the lowest effective dosage for the shortest duration consistent with treatment goals. Prolonged use of this class of medication often involves ongoing re-evaluation by a healthcare provider, as it is a Schedule IV controlled substance.


Q: What kind of research has been done on the long-term effects of Tradonal?

A: Studies used for regulatory approval often had limited follow-up durations for conditions like chronic pain. For this reason, official information indicates that the full extent of the drug’s long-term effects has not been fully established and remains a limitation of the current research.


Q: Where can I find reliable studies about Tradonal's effectiveness?

A: Authoritative information regarding the drug’s effectiveness, clinical data, and mechanism of action is found within the Clinical Studies and Pharmacology sections of official regulatory documents. Examples include the FDA Prescribing Information and the European Medicines Agency (EMA) Summary of Product Characteristics.


Q: What is the typical timeframe for seeing the full benefit of Tradonal?

A: For immediate-release forms, the onset of pain relief typically begins within one hour, with a peak effect in about two to three hours. For chronic pain management, the optimal sustained effect may be observed over time as the dose is gradually adjusted (titrated) by a healthcare professional.


Q: Why do some people experience dry mouth when taking Tradonal?

A: Dry mouth is listed in regulatory documents as one of the most common side effects of Tradonal. This effect is documented as a common adverse reaction, likely related to the drug's activity on the nervous system.


Q: Is Tradonal safe for people with diabetes?

A: Official research has included patient populations with painful diabetic neuropathy, suggesting it has been studied in this group. However, the regulatory label does not provide a general safety statement for all individuals with diabetes, and its use is a decision that requires evaluation by a healthcare professional.


Q: Are there any non-medical factors that can affect how Tradonal works?

A: Yes, non-medical factors can affect its action, most importantly the consumption of alcohol, which is associated with life-threatening effects. Regulatory documents also note that metabolism (how the body processes the drug) can vary significantly between individuals.


Q: What is Tradonal's mechanism of action in simple terms?

A: Tradonal works in two ways to relieve pain. It acts as a weak opioid to dampen the intensity of pain signals, and it affects the availability of certain brain chemicals like serotonin and norepinephrine, which are involved in the body's natural pain pathways.


Q: Is there a rebound effect when stopping Tradonal?

A: When the drug is stopped suddenly in patients who have developed physical dependence, regulatory documents confirm that withdrawal symptoms may occur. To minimize the risk of withdrawal, a healthcare professional will manage the gradual dose reduction, known as tapering.


Q: Are eye-related side effects common with Tradonal?

A: Yes, the official adverse reaction lists document that eye-related issues are possible. These commonly include visual disturbances, blurred vision, and miosis (pinpoint pupils).


Q: How often do people need to adjust their Tradonal dose?

A: Dose adjustments (titration) are highly individualized and depend on the patient's response. Regulatory instructions specify that for extended-release forms, dose increases should occur no more frequently than every five days.


Q: Does Tradonal show up on drug tests?

A: Yes. Since Tradonal (Tramadol) is a Schedule IV controlled substance and an opioid derivative, both the drug and its primary active metabolite can be detected on specific drug screening panels designed to look for these substances.


Q: What is the shelf life of Tradonal?

A: The shelf life is specified in the regulatory packaging and varies by the exact formulation and dosage form. Depending on the product, the shelf life is often stated to be between three and four years, provided the medicine is stored strictly at controlled room temperature and protected from moisture.


Q: Do other medicines make the side effects of Tradonal worse?

A: Yes. Taking Tradonal with other central nervous system (CNS) depressants (like tranquilizers or sedatives) can make side effects such as dizziness, drowsiness, and poor concentration more pronounced.


Q: Has Tradonal been approved in other countries?

A: Yes. The drug is reviewed and approved by regulatory bodies in multiple regions. Official product information is cited by authorities like the US FDA, the European Medicines Agency (EMA), and regulatory bodies in the UK and other major international regions.


Q: Are there any known drug interactions that make Tradonal less effective?

A: Yes. Regulatory documents warn that certain enzyme inducers, such as the drug Carbamazepine, can increase the metabolism of Tradonal. This may result in lower levels of the active form in the body, potentially reducing its pain-relieving effect.


Q: Why is it important to tell my doctor about all supplements when taking Tradonal?

A: It is important because some supplements, such as St. John's Wort, affect serotonin levels in the body. Taking these supplements with Tradonal can increase the risk of a dangerous condition called Serotonin Syndrome, which is explicitly noted in regulatory warnings.


Q: What should I do if a side effect of Tradonal seems unusual?

A: Official warnings and patient medication guides advise that any signs of serious side effects, such as severe breathing difficulties, seizure, or symptoms suggestive of Serotonin Syndrome, require immediate medical attention. If you observe an unusual side effect, it is important to seek immediate medical attention.


Q: Is it okay to crush or split Tradonal tablets?

A: For extended-release tablets or capsules, the regulatory label strictly indicates they must be swallowed whole. They should not be crushed, chewed, split, or dissolved, as this action bypasses the controlled-release mechanism and may lead to rapid drug release and potentially serious effects.


Q: Does Tradonal cause weight gain or loss?

A: Weight change is a documented adverse effect of Tradonal. Official regulatory labels list weight loss as an uncommon side effect, though it is not classified among the most common adverse reactions.


Q: Does Tradonal affect blood pressure or heart rate?

A: Yes, official warnings include a risk of Severe Hypotension, which is dangerously low blood pressure. Regulatory documents also list tachycardia (fast heart rate) and palpitations as documented side effects.

How should Tradonal be stored and disposed of?

Official Storage and Disposal Instructions

Tradonal (Tramadol Hydrochloride) must be stored and secured according to regulatory requirements to ensure stability and safety, particularly concerning child access.

Storage Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep the medication protected from light and excess moisture; do not store in the bathroom.
Container Rule Keep the medicine in its original container and ensure the container is tightly closed.
Child Safety Store securely out of the sight and reach of children and in a locked location, as accidental ingestion can be fatal.

Disposal of Unused Product

Official disposal guidelines for unused Tradonal vary by region but focus on immediate removal of the hazard. Take-back programs at pharmacies or authorized collectors are the preferred method. Where this is not available, U.S. guidance recommends immediately flushing the product down the toilet. Other disposal methods, such as mixing with unappealing substances (e.g., used coffee grounds) and placing in the trash, may be recommended for non-flushable forms or by local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tradonal found in:

A-Z Index: